Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection

Abstract Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Agata Antepowicz, Omar Habib, Freja Kirsebom, Cecilia Johansson, Deborah R. Gill, Stephen C. Hyde
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/02a847cbdd3747d0b7746de8f6676a1b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:02a847cbdd3747d0b7746de8f6676a1b
record_format	dspace
spelling	oai:doaj.org-article:02a847cbdd3747d0b7746de8f6676a1b2021-12-02T18:49:28ZLentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection10.1038/s41598-021-95150-z2045-2322https://doaj.org/article/02a847cbdd3747d0b7746de8f6676a1b2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95150-zhttps://doaj.org/toc/2045-2322Abstract Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing vectors 28 days prior to RSV challenge resulted in complete protection from RSV-induced weight loss. This approach offers prophylaxis against RSV infection, allowing for wider use and reduction in treatment costs in vulnerable populations.Agata AntepowiczOmar HabibFreja KirsebomCecilia JohanssonDeborah R. GillStephen C. HydeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Agata Antepowicz Omar Habib Freja Kirsebom Cecilia Johansson Deborah R. Gill Stephen C. Hyde Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
description	Abstract Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing vectors 28 days prior to RSV challenge resulted in complete protection from RSV-induced weight loss. This approach offers prophylaxis against RSV infection, allowing for wider use and reduction in treatment costs in vulnerable populations.
format	article
author	Agata Antepowicz Omar Habib Freja Kirsebom Cecilia Johansson Deborah R. Gill Stephen C. Hyde
author_facet	Agata Antepowicz Omar Habib Freja Kirsebom Cecilia Johansson Deborah R. Gill Stephen C. Hyde
author_sort	Agata Antepowicz
title	Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title_short	Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title_full	Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title_fullStr	Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title_full_unstemmed	Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title_sort	lentiviral and aav-mediated expression of palivizumab offer protection against respiratory syncytial virus infection
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/02a847cbdd3747d0b7746de8f6676a1b
work_keys_str_mv	AT agataantepowicz lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection AT omarhabib lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection AT frejakirsebom lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection AT ceciliajohansson lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection AT deborahrgill lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection AT stephenchyde lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection
_version_	1718377543992606720

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection

Ejemplares similares